Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 5, Issue 2, 2007, Pages 217-228

  Lyman, Gary H ^a   Kleiner, Jessica Malone ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Chemotherapy; Colony stimulating factors; Febrile neutropenia; Myeloid growth factors

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYELOID GROWTH FACTOR; NAVELBINE; PACLITAXEL; PREDNISONE; RITUXIMAB; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ARTICLE; CANCER PATIENT; CLINICAL PRACTICE; CONTROLLED STUDY; FEBRILE NEUTROPENIA; HUMAN; MEDICAL SOCIETY; PRACTICE GUIDELINE; PROPHYLAXIS; RISK ASSESSMENT;

EID: 33947249481     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2007.0021     Document Type: Article

References (29)

1. Dale DC, McCarter GC, Crawford J, et al. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw 2003;1:440-454.
2. Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymph 2003;44:2069-2076.
3. Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of the myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw 2005;3:557-571.
4. Kuderer NM, Dale D, Crawford J, et al. The morbidity, mortality and cost of febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-2266.
5. Lyman GH, Dale D, Crawford J. Incidence and predictors of low dose intensity in adjuvant breast cancer chemotherapy: anationwide study of community practices. J Clin Oncol 2003;21:4524-4531.
6. Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004;4302-4311.
7. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325: 164-170.
8. Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 2002;112:406-411.
9. Osby E, Hagberg H, Kvalov S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003;101:3840-3848.
10. Doorduijn JK, van der HB, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3041-3050.
11. Timmer-Bonte JN, de Boo TM, Smit HJ, et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. J Clin Oncol 2005;23:7974-7984.
12. Vogel C, Wojtukiewicz MZ, Caroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178-1184.
13. Kuderer NM, Crawford J, Dale DC, GH Lyman. Meta-analysis of prophylactic granulocyte colony-stimulating factor (G-CSF) in cancer patients receiving chemotherapy [abstract]. J Clin Oncol 2005; 23(Suppl 1):758. Abstract 8117.
14. Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005;10:427-437.
15. Lyman GH, Kuderer NM, Crawford J, et al. Prospective validation of a risk model for first cycle neutropenic complications in patients receiving cancer chemotherapy [abstract]. J Clin Oncol 2006; 24(Suppl 1):483. Abstract 8561.
16. Lyman GH, Lyman CG, Sanderson RA, Balducci L. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993;85:488-493.
17. Lyman GH, Kuderer N, Greene J, Balducci L. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 1998;34:1857-1864.
18. Lyman GH, Kuderer NM. Economics of hematopoietic growth factors. In: Morstyn G, Foote M, Lieschke GJ, eds. Cancer Drug Discovery and Development. Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics. Totowa, NJ: Humana Press Inc, 2004:409-443.
19. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994;12:2471-2508.
20. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000;18:3558-3585.
21. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin Oncol 2006;24: 3187-3205.
22. Crawford J, Althaus B, Armitage J, et al. NCCN myeloid growth factors clinical practice guidelines in oncology. J Natl Compr Canc Netw 2005;3:540-555.
23. Crawford J, Althaus B, Armitage J, et al. NCCN clinical practice guidelines in oncology. V1.2007. Available at http://www.nccn.org/professionals/ physician_gls/PDF/myeloid_growth.pdf. Accessed January 12, 2007.
24. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte colony-stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42: 2433-2453.
25. Repetto L, Biganzoli L, Koehne CH, et al. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 2003;39: 2264-2272.
26. The AGREE Collaboration. Appraisal of the Guidelines for Research and Evaluation (AGREE) Instrument. Available at: http://www.agreecollaboration.org. Accessed January 12, 2007.
27. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003;12:18-23.
28. Burgers JS, Fervers B, Haugh M, et al. International assessment of the quality of clinical practice guidelines in oncology using the Appraisal of Guidelines and Research and Evaluation Instrument. J Clin Oncol 2004;22:2000-2007.
29. Shanaeyfelt TM, Mayo-Snith MF, Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA 1999;281:1900-1905.